glecaprevir
Sign in to saveGlecaprevir (INN,) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir. Together they demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 838.9
- Has use
- medication
Show 1 more fact
- chemical formula
- C₃₈H₄₆F₄N₆O₉S
Sources (1)
via Wikidata · CC0
~3 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
{{Drugbox | IUPAC_name = (3aR,7S,10S,12R,21E,24aR)-7-tert-Butyl-N-{(1R,2R)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl}-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1H,10H-9,12-methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclonon adecino[11,12-b]quinoxaline-10-carboxamide | image = Glecaprevir.svg | image_class = skin-invert-image | width =
| tradename = Mavyret (combination with pibrentasvir) | Drugs.com = | licence_US = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = By mouth
Excerpted from Wikipedia’s “glecaprevir” article, available under the CC BY-SA 4.0 licence.